PHA 568487

PHA 568487 Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: EMMX Biotechnology LLC  
Tel: 888-539-0666
Email: info@emmx.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Jinan Jiuli Biotechnology Co. , Ltd.  
Tel: 15865264761
Email: 486064515@qq.com
Company Name: Nantong Hi-Future Biotechnology Co., Ltd  
Tel: +86-0513; 18051384581
Email: sales@chemhifuture.com
PHA 568487 Basic information
Product Name:PHA 568487
Synonyms:
CAS:527680-57-5
MF:C20H24N2O7
MW:404.41376
EINECS:
Product Categories:
Mol File:527680-57-5.mol
PHA 568487 Structure
PHA 568487 Chemical Properties
solubility Soluble to 100 mM in water and to 100 mM in DMSO
form Powder
Safety Information
MSDS Information
PHA 568487 Usage And Synthesis
UsesPHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR)[1][2].PHA 568487 reduces neuroinflammation and oxidative stress[2]. PHA-568487 has rapid brain penetration[3].
in vivo

PHA 568487 attenuates neuronal injury and behavioral dysfunction in mice with ischemic stroke only and ischemic stroke plus tibia fracture[2].
PHA 568487 (1.25 mg/kg; i.p.; treated daily)-treated ischemic rats shows a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome[4].

Animal Model:C57BL/6J male mice (10-12 weeks old)[2]
Dosage:PHA 568487 (PHA; 0.4 and 0.8 mg/kg); Methyllycaconitine (MLA; 4 and 6 mg/kg)
Administration:Injected intraperitoneally once on day 1, or twice on days 1 and 2, after pMCAO
Result:Injection of PHA (0.8 mg/kg) and MLA (6 mg/kg) on days 1 and 2 after pMCAO yielded the best effect on infarct volume and behavior tests.
Animal Model:Adult male Sprague-Dawley rats (297 6±8.3 g)[4]
Dosage:1.25 mg/kg
Administration:I.p.;0.1 mL; treated daily
Result:Showed a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome.
storageDesiccate at RT
References[1] F Barclay Shilliday,et al. Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist. Drug Metab Lett.2010 Aug;4(3):162-72. PMID:20642449
[2] Zhenying Han,et al. Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture. J Neurochem.2014 Nov;131(4):498-508. DOI:10.1111/jnc.12817
[3] Dingquan Zou,et al.Activation of Alpha-7 Nicotinic Acetylcholine Receptor Reduces Brain Edema in Mice with Ischemic Stroke and Bone Fracture. Mol Neurobiol.2017 Dec;54(10):8278-8286. DOI:10.1007/s12035-016-0310-8
[4] Lorena Colás, et al. In vivo imaging of Α7 nicotinic receptors as a novel method to monitor neuroinflammation after cerebral ischemia. Glia.2018 Aug;66(8):1611-1624. DOI:10.1002/glia.23326
PHA 568487 Preparation Products And Raw materials
Raw materials1,4-Benzodioxane-6-carboxylic acid-->3-Aminoquinuclidine dihydrochloride
Tag:PHA 568487(527680-57-5) Related Product Information
3-(2,4-dimethoxybenzylidene)anabaseine Mecamylamine hydrochloride N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide CYTISINE ALPHA-BUNGAROTOXIN Carbachol